Project Grant HT94252310970

Federal Grant Award Summary Rheumagen, Inc. received a $2 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 15, 2025, with completion targeted for August 31, 2026. The award funds development of RG0401, an ex vivo autologous CD34+ hematopoietic progenitor cell-based gene therapy designed to treat refractory rheumatoid arthritis...

Federal Grant Award Summary: Bispecific Biologic for Rheumatoid Arthritis Therapy Knoubis Bio Inc. received a $312,323 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a novel bispecific biologic therapeutic for rheumatoid arthritis (RA). The award was obligated on July 15, 2025, with a project completion date of June 30, 2026. Under this...

This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...

This Project Grant award of $405,350.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to characterize lipid droplets in macrophage subsets and determine if manipulating lipid droplet content can shift macrophage function, with the goal of uncovering new therapeutic targets for systemic lupus erythematosus (SLE). The award recipient is The...

This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...

Federal Project Grant Award Summary Navega Therapeutics, Inc. received a $297,327 Project Grant award dated September 18, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to reformulate NT-Z001, an epigenetic gene therapy targeting the NAV1.7 sodium channel for rheumatoid arthritis (RA) pain management. The project, scheduled for completion by August 31, 2026, will...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...

Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $320,417 Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) on August 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a five-year research initiative through July 31, 2030, focused on deciphering complement-dependent macrophage phenotypes in rheumatoid arthritis...

Project Grant Summary Rutgers The State University of New Jersey, Robert Wood Johnson Health Sciences (RBHS)-School of Nursing received a $637,018 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded August 7, 2025, with completion targeted for June 30, 2030. The grant funds basic and translational research investigating the role of natural killer (NK)...

This Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of reverse transendothelial migration of neutrophils in inflammation resolution. The $366,797 award, with a project period from Sep 24, 2024 to Aug 31, 2026, aims to provide new insights into the mechanisms by which certain inflammatory mediators,...